Mattia Galanti, Luigi Boccuto
Artificial Intelligence (AI) provides remarkable tools in modern medicine and is widely used to process high-throughput data and integrate different omics-derived models. In recent years, AI, and particularly generative AI (GenAI), has been utilized to design clinical trials for neurobehavioral disorders due to the complexity of variables presented by these conditions. However, ethical and methodological limitations suggest a supporting rather than leading role of AI in the design, management, and interpretation of clinical trials, and caution against moving the human component away from the evaluation of the qualitative as well as quantitative impact of a new treatment protocol.